Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...

Type 2 diabetes mellitus (T2DM) is a major public health challenge in India, with an estimated 101 million individuals ...

Sitagliptin, metformin (as HCl) ext-rel; 50mg/500mg, 50mg/1000mg, 100mg/1000mg; tabs. Individualize. Swallow whole. Take once daily with a meal, preferably in the evening. Not currently treated ...

A recently published study examined the effects of adding sitagliptin—an inhibitor of dipeptidyl peptidase 4—to therapy for patients with type 2 diabetes mellitus who were inadequately ...

Researchers from the US have shown that combination therapy with sitagliptin and metformin results in a substantial and additive glycemic improvement in patients with type 2 diabetes. Sitagliptin ...

Hypoglycemia was reported more commonly with the use of sitagliptin in combination with a sulfonylurea, a class of medicines known to cause hypoglycemia. When used in combination with a ...